Bad Blood
Autor John Carreyrouen Limba Engleză Paperback – 28 ian 2020
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: The technology didn't work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings--from journalists to their own employees.
Preț: 76.48 lei
Puncte Express: 115
Carte disponibilă
Livrare economică 08-15 iunie
Livrare express 28 mai-03 iunie pentru 16.63 lei
Specificații
ISBN-13: 9780593081648
ISBN-10: 0593081641
Pagini: 352
Dimensiuni: 171 x 104 x 31 mm
Greutate: 0.23 kg
Ediția:International
Editura: Random House LLC US
Colecția Vintage
ISBN-10: 0593081641
Pagini: 352
Dimensiuni: 171 x 104 x 31 mm
Greutate: 0.23 kg
Ediția:International
Editura: Random House LLC US
Colecția Vintage
Notă biografică
John Carreyrou, a two-time Pulitzer Prize winner, was a reporter at The Wall Street Journal for twenty years. For his extensive coverage of Theranos, Carreyrou was awarded the George Polk Award for Financial Reporting, the Gerald Loeb Award for Distinguished Business and Financial Journalism in the category of beat reporting, and the Barlett & Steele Silver Award for Investigative Business Journalism. Bad Blood was named the Financial Times and McKinsey Business Book of the Year. Carreyrou lives in Brooklyn, New York, with his wife and three children.
Descriere
Descriere de la o altă ediție sau format:
The shocking true story of the biggest corporate fraud since Enron, a gripping cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.
The shocking true story of the biggest corporate fraud since Enron, a gripping cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.